|
|
|
|
|
The Niche
|
Stem Cell & Regenerative Med Newsletter
|
|
|
|
|
|
Weekly stem cell reads: space, plagiarism, HIV, diabetes, more
|
|
|
|
I took a cross-country road trip earlier this month that was pretty amazing and barely thought about stem cell research for the first time in years. We did run across one stem cell clinic in Florida by accident. I'll write about that trip soon, but first we have our weekly reads including some very cool new stem cell papers. Longtime …
|
|
|
|
|
|
|
|
In big shift Dr. Robert Lanza exits Astellas
|
|
|
|
The recent news of Vertex Pharma buying small stem cell biotech ViaCyte and Doug Melton moving to Vertex brought to mind an old stem cell biotech called Advanced Cell Technology (ACT) and its leader, stem cell biologist Dr. Robert Lanza. Years ago, big pharma firm Astellas bought ACT and Lanza moved to be a leader of regenerative medicine efforts at Astellas. The …
|
|
|
|
|
|
|
|
ViaCyte purchase puts Vertex in driver's seat on stem cells for diabetes
|
|
|
|
When I'm asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It's really that promising even though there are no guarantees, of course. Now …
|
|
|
|
|
|
